Clinical Trial

A Multicenter Open-label Phase II Study of Cemiplimab Plus Chemotherapy, Selected on the Basis of Baseline Cytidine Deaminase Activity, in Advanced Squamous Non-small Cell Lung Cancer

Name: A Multicenter Open-label Phase II Study of Cemiplimab Plus Chemotherapy, Selected on the Basis of Baseline Cytidine Deaminase Activity, in Advanced Squamous Non-small Cell Lung Cancer — clinical trial record (NCT07418931)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: CECYDE

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a multicenter phase II study enrolling treatment- naïve patients with metastatic or recurrent squamous carcinoma of the lung

Trial Details

NCT Number	NCT07418931
Lead Sponsor	Gruppo Oncologico Italiano di Ricerca Clinica
Conditions	Advanced Squamous Non-Small Cell Lung Cancer
Enrollment	108 participants
Start Date	2026-05
Primary Completion	2028-05 (estimated)
Study Completion	2030-11 (estimated)
Updated on ClinicalTrials.gov	2026-02-18